GLIOMA, MALIGNANT

This early-stage trial tests a vaccine made from small pieces of proteins (peptides) found on glioblastoma cells. The goal is to see if the vaccine is safe and can train the immune system to fight the cancer. The study includes 24 adults with a specific type of newly diagnosed, u…

This study tests a drug called niraparib in people with two types of brain tumors: newly diagnosed glioblastoma and recurrent IDH-mutant glioma with ATRX loss. The goal is to see if the drug reaches the tumor and slows its growth. Up to 42 participants will receive niraparib befo…

This early-stage trial tests a drug called AZD1390 combined with radiation therapy in people with a fast-growing brain tumor (grade 4 glioma). About 97 participants with either new or returning tumors will receive the drug to see how well it reaches the tumor and if it helps cont…

This early-phase trial enrolls 16 adults with recurrent IDH-mutant gliomas who are scheduled for surgery. Participants take niraparib for one month before their operation. The main goal is to measure how much drug gets into the tumor and how it affects cancer cell activity, not t…

This study looks at how brain tumors (gliomas) weaken the body's immune system. Researchers will use special MRI scans and tissue samples from 31 adult patients to find markers of immune suppression. The goal is to better understand the disease, not to test a new treatment.